The Blockbusters No One Talks About
Executive Summary
Drugs like Nexium, Lipitor, Lovenox and Plavix lost patent protection years ago, but continue to generate blockbuster level sales. Here's a look at the blockbuster brands that have stood the test of (generic) time.
You may also be interested in...
Crestor Generics To Launch After 12-Day Delay
AstraZeneca's legal gambit results in almost two more weeks of sales for the statin even though the court ultimately agreed with FDA on labeling carve-out for orphan indication.
FDA approval of generic Lovenox sparks debate and lawsuit
The US FDA approval of the first generic version of Sanofi-Aventis's Lovenox (enoxaparin sodium) to Novartis' generics arm Sandoz, which uses technology from Momenta Pharmaceuticals, has caused a buzz because the agency has treated the application like a standard but yet complicated ANDA and did not require full clinical studies.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.